AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890)...

Related Keywords

Puerto Rico , Illinois , United States , Chicago , America , American , Coll Cardiol , Michael Strapazon , Jessica Akopyan , Michellel Odonoghue , Clin Lipidol , Arterioscler Thromb Vasc , Davidm Reese , Instagram , Amgen , Linkedin , Twitter , American Heart Association Scientific Sessions , Science Session Of The American Heart Association , Therapeutics Inc , Teneobio Inc , Kyowa Kirin Co Ltd , Drug Administration , Beigene Ltd , Most Sustainable Companies , Exchange Commission , Youtube , Study Group At Brigham , Chemocentryx Inc , Olpasiran Reduced Lipoprotein , More Than , Patients With Established , Outcomes Trial Based , Simultaneously Published , New England Journal , Breaking Science Session , American Heart Association , Scientific Sessions , Senior Investigator , Global Principal , Olpasiran Trials , Cardiovascular Events And Lipoprotein , Dow Jones Industrial Average , Five Prime Therapeutics , With Small Interfering , Thromb Vasc , Thousand Oaks ,